Physician profile
Katie E Cameron
NPI 1942511753
$455.89
in general payments reported to CMS, 2019-2025
14 companies · $10.95 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $27.87 · 2021: $13.44 · 2022: $71.33 · 2023: $31.06 · 2024: $51.36 · 2025: $10.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $101.24 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $60.95 | 2019-2023 | Jornay Pm |
| Lilly USA, LLC | $58.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.42 | 2019 | |
| Abbvie INC. | $28.95 | 2022 | |
| Glaxosmithkline, LLC. | $28.73 | 2024 | Bexsero, Pediarix, Rotarix |
| Novo Nordisk INC | $27.41 | 2019-2022 | |
| Medline Industries Lp | $22.63 | 2024 | |
| Organon LLC | $20.40 | 2023-2025 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $13.44 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.92 | 2022 | |
| Genentech USA, INC. | $11.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.